Drug Trial Radar · NCT00417079
XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Mar 10, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
755
Actual
Start
Jan 2007
Primary completion
Sep 2009
Study completion Sep 2009
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Dec 29, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, open-label, multi-center study comparing the safety and efficacy of XRP6258 plus prednisone to mitoxantrone plus prednisone in the treatment of hormone refractory metastatic prostate cancer previously treated with a Taxotere®-containing regimen. The primary objective is overall survival. Secondary objectives include progression free survival, overall response rate, prostate-specific antigen (PSA) response/progression, pain response/progression, overall safety, and pharmacokinetics. Patients will be treated until disease progression, death, unacceptable toxicity, or for a maximum of 10 cycles. Patients will have long-term follow-up for a maximum of up to 2 years.
Conditions
- Neoplasms
- Prostatic Neoplasms
Interventions
cabazitaxel (XRP6258) (RPR116258)Drug
25 mg/m\^2 administered by intravenous (IV) route over 1 hour on day 1 of each 21-day cycle
mitoxantroneDrug
12 mg/m\^2 administered by intravenous (IV) route over 15-30 minutes on day 1 of each 21-day cycle
prednisoneDrug
10 mg daily administered by oral route
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: From the date of randomization up to 104 weeks (study cut-off)
Locations
26 sites in 26 countries. Site status is shown where the registry gives one.
sanofi-aventis US
Bridgewater, New Jersey
sanofi-aventis Argentina
Buenos Aires, Argentina
sanofi-aventis Belgium
Diegem, Belgium
sanofi-aventis Brazil
São Paulo, Brazil
sanofi-aventis Canada
Laval, Quebec, Canada
sanofi-aventis Chile
Santiago, Chile
sanofi-aventis Czech Republic
Prague, Czechia
sanofi-aventis Denmark
Hørsholm, Denmark
sanofi-aventis Finland
Helsinki, Finland
sanofi-aventis France
Paris, France
sanofi-aventis Germany
Berlin, Germany
Sanofi-Aventis Hungaria
Budapest, Hungary
sanofi-aventis India
Mumbai, India
sanofi-aventis Italy
Milan, Italy
sanofi-aventis Mexico
México, Mexico
sanofi-aventis Netherlands
Gouda, Netherlands
sanofi-aventis Russia
Moscow, Russia
sanofi-aventis Singapore
Singapore, Singapore
sanofi-aventis Slovakia
Bratislava, Slovakia
sanofi-aventis South Africa
Midrand, South Africa
sanofi-aventis South Korea
Seoul, South Korea
sanofi-aventis Spain
Barcelona, Spain
sanofi-aventis Sweden
Bromma, Sweden
sanofi-aventis Taiwan
Taipei, Taiwan
sanofi-aventis Turkey
Istanbul, Turkey (Türkiye)
sanofi-aventis UK
Guildford, Surrey, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.